In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila

Molecular Brain

Volumn 7, Issue 1, 2014, Pages

  Wang, Hua Shan ^a   Toh, Joanne ^a   Ho, Patrick ^a   Tio, Murni ^a   Zhao, Yi ^b   Tan, Eng King ^a,b,c  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Drosophila; Parkinson's disease; Retromer complex; VPS35

Indexed keywords

D620N PROTEIN; L77M PROTEIN; P316S PROTEIN; PROTEIN; ROTENONE; TOXIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VPS35 PROTIEN; DROSOPHILA PROTEIN; VESICULAR TRANSPORT PROTEIN; VPS35 PROTEIN, DROSOPHILA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DROSOPHILA; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VIVO STUDY; INSECT GENETICS; LIFESPAN; LOCOMOTION; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENICITY; PHENOTYPE; VPS35 GENE; ANIMAL; DROSOPHILA MELANOGASTER; DRUG EFFECTS; GENETICS; METABOLISM; MOTOR ACTIVITY; MUTATION; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; HUMANS; MOTOR ACTIVITY; MUTATION; NERVE DEGENERATION; NEURONS; ROTENONE; VESICULAR TRANSPORT PROTEINS;

EID: 84907983816     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/s13041-014-0073-y     Document Type: Article

References (24)

1. Pathogenic mutations in Parkinson disease. EK Tan, LM Skipper, Hum Mutat 2007 28 7 641 653 10.1002/humu.20507 17385668
2. The role of retromer in neurodegenerative disease. C Skinner, M Seaman, C Skinner, M Seaman, Research and Perspectives in Alzheimer's Disease Springer Berlin, Heidelberg, St. George-Hyslop PH, Mobley WCC, Yves C, 2009 125 140
3. Retromer. JS Bonifacino, JH Hurley, Curr Opin Cell Biol 2008 20 4 427 436 10.1016/j.ceb.2008.03.009 18472259
4. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. A Zimprich, A Benet-Pagès, W Struhal, E Graf, SH Eck, MN Offman, D Haubenberger, S Spielberger, EC Schulte, P Lichtner, SC Rossle, N Klopp, E Wolf, K Seppi, W Pirker, S Presslauer, B Mollenhauer, R Katzenschlager, T Foki, C Hotzy, E Reinthaler, A Harutyunyan, R Kralovics, A Peters, F Zimprich, T Brücke, W Poewe, E Auff, C Trenkwalder, B Rost, et al. Am J Hum Genet 2011 89 1 168 175 10.1016/j.ajhg.2011.06.008 21763483
5. VPS35 mutations in Parkinson disease. C Vilariño-Güell, C Wider, OA Ross, JC Dachsel, JM Kachergus, SJ Lincoln, AI Soto-Ortolaza, SA Cobb, GJ Wilhoite, JA Bacon, B Behrouz, HL Melrose, E Hentati, A Puschmann, DM Evans, E Conibear, WW Wasserman, JO Aasly, PR Burkhard, R Djaldetti, J Ghika, F Hentati, A Krygowska-Wajs, T Lynch, E Melamed, A Rajput, AH Rajput, A Solida, RM Wu, RJ Uitti, et al. Am J Hum Genet 2011 89 1 162 167 10.1016/j.ajhg.2011.06.001 21763482
6. VPS35 mutation in Japanese patients with typical Parkinson's disease. M Ando, M Funayama, Y Li, K Kashihara, Y Murakami, N Ishizu, C Toyoda, K Noguchi, T Hashimoto, N Nakano, R Sasaki, Y Kokubo, S Kuzuhara, K Ogaki, C Yamashita, H Yoshino, T Hatano, H Tomiyama, N Hattori, Mov Disord 2012 27 11 1413 1417 10.1002/mds.25145 22991136
7. VPS35 gene variants are not associated with Parkinson's disease in the mainland Chinese population. JF Guo, QY Sun, ZY Lv, RL Yu, K Li, YH Zhang, JY Tian, K Xia, XX Yan, BS Tang, Parkinsonism Relat Disord 2012 18 8 983 985 10.1016/j.parkreldis.2012.05.002 22673036
8. Identification of VPS35 mutations replicated in French families with Parkinson disease. S Lesage, C Condroyer, S Klebe, A Honoré F Tison, C Brefel-Courbon, A Dürr, A Brice, Neurology 2012 78 18 1449 1450 10.1212/WNL.0b013e318253d5f2 22517097
9. Sheerin UM, Charlesworth G, Bras J, Guerreiro R, Bhatia K, Foltynie T, Limousin P, Silveira-Moriyama L, Lees A, Wood N: Screening for VPS35 mutations in Parkinson's disease. Neurobiol Aging 2012, 33 (4):838. e1-838.e5.
10. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. M Sharma, JPA Ioannidis, JO Aasly, G Annesi, A Brice, L Bertram, M Bozi, M Barcikowska, D Crosiers, CE Clarke, MF Facheris, M Farrer, G Garraux, S Gispert, G Auburger, C Vilariño-Güell, GM Hadjigeorgiou, AA Hicks, N Hattori, BS Jeon, Z Jamrozik, A Krygowska-Wajs, S Lesage, CM Lill, JJ Lin, T Lynch, P Lichtner, AE Lang, C Libioulle, M Murata, et al. J Med Genet 2012 49 11 721 726 10.1136/jmedgenet-2012-101155 23125461
11. Drosophila Vps35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. VI Korolchuk, MM Schütz, C Gómez-Llorente, J Rocha, NR Lansu, SM Collins, YP Wairkar, IM Robinson, CJ O'Kane, J Cell Sci 2007 120 24 4367 4376 10.1242/jcs.012336 18057029
12. Dong B, Kakihara K, Otani T, Wada H, Hayashi S: Rab9 and retromer regulate retrograde trafficking of luminal protein required for epithelial tube length control. Nat Commun 2013, 4: 1358.
13. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. DA MacLeod, H Rhinn, T Kuwahara, A Zolin, G Di Paolo, BD McCabe, BD MacCabe, KS Marder, LS Honig, LN Clark, SA Small, A Abeliovich, Neuron 2013 77 3 425 439 10.1016/j.neuron.2012.11.033 23395371
14. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. AJ Whitworth, DA Theodore, JC Greene, H Beneš PD Wes, LJ Pallanck, Proc Natl Acad Sci 2005 102 22 8024 8029 10.1073/pnas.0501078102 15911761
15. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. C Wang, R Lu, X Ouyang, MWL Ho, W Chia, F Yu, KL Lim, J Neurosci 2007 27 32 8563 8857 10.1523/JNEUROSCI.0218-07.2007 17687034
16. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. CH Ng, SZS Mok, C Koh, X Ouyang, ML Fivaz, EK Tan, VL Dawson, TM Dawson, F Yu, KL Lim, J Neurosci 2009 29 36 11257 11262 10.1523/JNEUROSCI.2375-09.2009 19741132
17. Functional architecture of the retromer cargo-recognition complex. A Hierro, AL Rojas, R Rojas, N Murthy, G Effantin, AV Kajava, AC Steven, JS Bonifacino, JH Hurley, Nature 2007 449 7165 1063 1067 10.1038/nature06216 17891154
18. Vps29 has a phosphoesterase fold that acts as a protein interaction scaffold for retromer assembly. BM Collins, CF Skinner, PJ Watson, MNJ Seaman, DJ Owen, Nat Struct Mol Biol 2005 12 7 594 602 10.1038/nsmb954 15965486
19. The structure and function of the retromer protein complex. BM Collins, Traffic 2008 9 11 1811 1822 10.1111/j.1600-0854.2008.00777.x 18541005
20. Zavodszky E, Seaman MN, Moreau K, Jimenez-Sanchez M, Breusegem SY, Harbour ME, Rubinsztein DC: Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy. Nat Commun 2014, 5: 3828.
21. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. J Follett, SJ Norwood, NA Hamilton, M Mohan, O Kovtun, S Tay, Y Zhe, SA Wood, GD Mellick, PA Silburn, BM Collins, A Bugarcic, RD Teasdale, Traffic 2014 15 2 230 244 10.1111/tra.12136 24152121
22. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. E Tsika, L Glauser, R Moser, A Fiser, G Daniel, UM Sheerin, A Lees, JC Troncoso, PA Lewis, R Bandopadhyay, BL Schneider, DJ Moore, Hum Mol Genet 2014 23 17 4621 4638 10.1093/hmg/ddu178 24740878
23. Vps35 mediates vesicle transport between the mitochondria and peroxisomes. E Braschi, V Goyon, R Zunino, A Mohanty, L Xu, HM McBride, Curr Biol 2010 20 14 1310 1315 10.1016/j.cub.2010.05.066 20619655
24. Pathogenic mutation in VPS35 impairs its protection against MPP(+) cytotoxicity. F Bi, F Li, C Huang, H Zhou, Int J Biol Sci 2013 9 2 149 155 10.7150/ijbs.5617 23411763